Pharmacokinetics and safety of NM441, a new quinolone, in healthy male volunteers

DOI 12 Citations 12 References

Bibliographic Information

Other Title
  • NM441の臨床第I相試験

Search this article

Abstract

The safety and pharmacokinetics of NM441, a prodrug of a new thiazeto-quinoline carboxylic acid derivative, NM394, were evaluated in healthy male volunteers given the drug orally in single doses of 20, 50, 100, 200 and 400mg, and multiple doses of 300mg twice daily for 6.5 days. No remarkable abnormalities were observed in symptoms, physical tests, laboratory tests, electrocardiogram (ECG), electroencephalogram (EEG) or equilibrium test. The mean plasma concentrations of active metabolite NM394 peaked between 0.5 and 1.0 hours, and the maximum concentrations were 0.68, 1.09 and 1.88/2g/ml at doses of 100, 200 and 400mg, respectively. The mean half-lives were 7.7 to 8.9 hours and were not affected by dose. The mean urinary excretion rates of NM394 were 46.0, 38.3 and 30.6% of the doses within 48 hours, respectively, and other metabolites were excreted in urine by 7% the doses. The salivary concentrations of NM394 were approximately 20% of the plasma concentrations. The mean fecal excretion rates of NM394 and NM441 were 52.9 and 4.2%, respectively within 72 hours after dosing of 400mg. The Cmax, AUC and urinary excretion rates were not altered by food intake, whereas the Tmax was prolonged slightly. In the multipledose study, the steady state of plasma concentration of NM394 was achieved on day 3 or 4, and further accumulation did not occur thereafter. The mean urinary excretion rate of NM394 was 49.0% during and 48 hours after the multiple administration. The acceptable safety and tolerance and defined pharmacokinetic characteristics of NM441 supports further testing.

Journal

Citations (12)*help

See more

References(12)*help

See more

Keywords

Details 詳細情報について

Report a problem

Back to top